Dermira vets license back candidates from Eli Lilly to launch their own upstart

Nicole DeFeudis

Editor

About a year after Eli Lilly absorbed Dermira in a $1 billion buyout, the dermatology company’s co-founders are licensing back three inflammatory disease programs …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Dermira vets license back candidates from Eli Lilly to launch their own upstart

Nicole DeFeudis

Editor

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Der­mi­ra vets li­cense back can­di­dates from Eli Lil­ly to launch their own up­start

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Dermira vets license back candidates from Eli Lilly to launch their own upstart